Form 4: HeartSciences Director Receives 15,000 RSU Grant

HeartSciences Inc. Director Brian Szymczak was granted 15,000 Restricted Stock Units, subject to specific vesting conditions including shareholder approval and performance targets.

Summary

• Brian Szymczak, a Director of HeartSciences Inc. (HSCS), was granted 15,000 Restricted Stock Units (RSUs).
• The RSUs were granted under the Issuer's 2023 Equity Incentive Plan (as amended), following approval by the Board of Directors.
• Each vested RSU will be settled by the delivery of one share of HeartSciences Inc. common stock.
• Vesting is contingent on two main conditions: (i) shareholder approval of any amendment or modification to or restatement of the Plan, and (ii) continuous service on the Board through the applicable vesting dates.
• Time-based vesting: 50% of the RSUs shall vest on the one-year anniversary of the grant date, and thereafter, 1/8th shall vest on each subsequent quarterly anniversary, leading to full vesting on the two-year anniversary of the grant date.
• Accelerated vesting: 100% of the RSUs shall vest upon a Change of Control (as defined in the Plan) or if the Issuer achieves $250,000 or more in revenue in any fiscal quarter ending after the grant date.

Sentiment

Score: 6

Explanation: Slightly positive as it aligns director incentives with company performance and shareholder value, though it introduces potential future dilution.

Positives

• The RSU grant incentivizes Director Brian Szymczak to contribute to the company's long-term success and shareholder value.
• Director compensation is directly tied to company performance through a revenue target of $250,000 in a fiscal quarter, and strategic events like a Change of Control.
• The structure aligns the director's interests with the company's growth and strategic objectives.

Negatives

• Potential future dilution for existing shareholders upon the vesting and conversion of RSUs into common stock.
• The grant is contingent on shareholder approval of the 2023 Equity Incentive Plan amendment, introducing a potential uncertainty.

Risks

• The RSUs may not vest if shareholders do not approve the amendment or modification to or restatement of the 2023 Equity Incentive Plan.
• The RSUs may not fully vest if Brian Szymczak does not continuously serve on the Board through each applicable vesting date.
• Achievement of the $250,000 quarterly revenue target is not guaranteed and depends on future company performance.

Future Outlook

The future outlook for the granted RSUs is contingent on several factors: shareholder approval of the equity plan amendment, the director's continuous service, and the company's ability to achieve a quarterly revenue of $250,000 or more, or a Change of Control event. These conditions aim to align the director's interests with the company's growth and strategic objectives.

Industry Context

This announcement pertains to an individual equity grant to a director and does not directly relate to broader industry trends or competitive landscape analysis.

Corporate Governance

Stakeholder Impact

• Shareholders: Will need to vote on the amendment to the 2023 Equity Incentive Plan. Potential future dilution from RSU conversion.
• Director (Brian Szymczak): Receives equity incentive tied to company performance and continued service, aligning personal interests with company success.

Next Steps

• Shareholder vote on the amendment or modification to or restatement of the 2023 Equity Incentive Plan.
• Monitoring of Brian Szymczak's continuous service on the Board.
• Monitoring of HeartSciences Inc.'s quarterly revenue performance for accelerated vesting conditions.

Key Dates

Keywords

HeartSciences Inc., HSCS, Restricted Stock Units, RSU grant, insider transaction, Form 4, equity incentive plan, director compensation, vesting conditions, shareholder approval, revenue target, Change of Control